Viking Therapeutics announced progress in its Phase 3 trials for VK2735, a dual GLP-1/GIP agonist for obesity, including subcutaneous and oral formulations. Positive results from a maintenance dosing study support flexible long-term treatment options. The company also nears completion of a Phase 1 study for VK3019, an amylin agonist. With $960 million in cash from recent financings, Viking is well-funded to complete trials and prepare for potential commercial launch of VK2735 in 2027.
Viking Therapeutics' third quarter 2026 financial results and corporate update provide context for health-sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 03:21 WIB: Among 150 priced health-sector US stocks, 103 rose and 46 fell today. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) at USD 13.33 with a 1-day change of +18.28% and a Pluang order activity split of 45% Sell / 55% Buy, NUWE (Nuwellis Inc) at USD 6.25 with +17.26% change and 74% Sell / 26% Buy order activity, and TDOC (Teladoc Health Inc) at USD 7.55 with +17.05% change and a typical hold time on Pluang of 39 days.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
Blockchain.com has launched TRX options trading, providing easier access to TRON's native token through its platform. This move expands the TRON ecosystem's reach by simplifying options trading for retail and institutional users worldwide. TRON, know...
